Exodus Point Capital Management, LP Aerie Pharmaceuticals Inc Transaction History

Exodus Point Capital Management, LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$6.37 - $15.23 $303,243 - $725,024	47,605 New	47,605 $720,000
Q2 2022 Aug 19, 2022	SELL	$4.95 - $9.16 $371,730 - $687,888	-75,097 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$5.64 - $9.8 $73,083 - $126,988	-12,958 Reduced 14.72%	75,097 $683,000
Q4 2021 Feb 11, 2022	BUY	$7.02 - $13.33 $480,083 - $911,612	68,388 Added 347.73%	88,055 $618,000
Q3 2021 Nov 15, 2021	SELL	$11.32 - $16.63 $219,823 - $322,937	-19,419 Reduced 49.68%	19,667 $224,000
Q2 2021 Aug 16, 2021	BUY	$15.16 - $18.97 $114,109 - $142,787	7,527 Added 23.85%	39,086 $626,000
Q1 2021 May 17, 2021	BUY	$13.12 - $20.9 $414,054 - $659,583	31,559 New	31,559 $564,000
Q3 2020 Nov 16, 2020	SELL	$10.46 - $14.46 $282,555 - $390,607	-27,013 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$12.0 - $16.13 $324,156 - $435,719	27,013 New	27,013 $399,000
Q4 2019 Feb 14, 2020	SELL	$17.72 - $25.1 $348,056 - $493,014	-19,642 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$18.41 - $28.0 $40,888 - $62,188	2,221 Added 12.75%	19,642 $378,000
Q2 2019 Aug 14, 2019	BUY	$28.97 - $48.21 $504,686 - $839,866	17,421 New	17,421 $515,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.